Ibogaine block of the NMDA receptor

In vitro and in vivo studies

Kang Chen, Tushar G. Kokate, Sean D. Donevan, F. Ivy Carroll, Michael A Rogawski

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Ibogaine is an hallucinogenic indole alkaloid claimed to have anti- addictive properties. Although its mechanism of action is unknown, binding studies have indicated that the drug may interact with N-methyl-D-aspartate (NMDA) receptors. We further investigated the nature of the interaction between ibogaine and NMDA receptors in voltage clamp and binding studies, and sought to confirm that the drug has NMDA receptor blocking activity in vivo. In whole-cell recordings from cultured rat hippocampal neurons, ibogaine caused a slow, concentration-dependent block of NMDA-induced currents (IC50, 3.1 μM at -60 mV). In contrast, ibogaine failed to affect either kainate- or γ-aminobutyric acid-evoked currents. The blockade of NMDA currents was use- and voltage-dependent, and the long lasting ibogaine block could be occluded by coapplication of Mg2+. Ibogaine also inhibited equilibrium [3H]dizocilpine binding to NMDA receptors in rat forebrain membranes (IC50, 3.2 μM). We conclude that ibogaine is an open channel NMDA receptor antagonist. Administration of ibogaine to mice resulted in complete protection in the maximal electroshock test (ED50, 31 mg/kg, i.p.) and partial protection against NMDA-induced lethality, confirming that ibogaine can block NMDA receptors in vivo.

Original languageEnglish (US)
Pages (from-to)423-431
Number of pages9
JournalNeuropharmacology
Volume35
Issue number4
DOIs
StatePublished - Apr 1996
Externally publishedYes

Fingerprint

Ibogaine
N-Methyl-D-Aspartate Receptors
N-Methylaspartate
Inhibitory Concentration 50
Indole Alkaloids
Aminobutyrates
In Vitro Techniques
Electroshock
Dizocilpine Maleate
Kainic Acid
Patch-Clamp Techniques
Prosencephalon
Pharmaceutical Preparations

Keywords

  • [H]dizocilpine binding
  • hippocampus
  • Ibogaine
  • maximal electroshock (MES) test
  • NMDA receptor
  • seizure
  • voltage clamp recording

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Ibogaine block of the NMDA receptor : In vitro and in vivo studies. / Chen, Kang; Kokate, Tushar G.; Donevan, Sean D.; Carroll, F. Ivy; Rogawski, Michael A.

In: Neuropharmacology, Vol. 35, No. 4, 04.1996, p. 423-431.

Research output: Contribution to journalArticle

Chen, Kang ; Kokate, Tushar G. ; Donevan, Sean D. ; Carroll, F. Ivy ; Rogawski, Michael A. / Ibogaine block of the NMDA receptor : In vitro and in vivo studies. In: Neuropharmacology. 1996 ; Vol. 35, No. 4. pp. 423-431.
@article{a830a871839c4b24b8c0d88d6749b325,
title = "Ibogaine block of the NMDA receptor: In vitro and in vivo studies",
abstract = "Ibogaine is an hallucinogenic indole alkaloid claimed to have anti- addictive properties. Although its mechanism of action is unknown, binding studies have indicated that the drug may interact with N-methyl-D-aspartate (NMDA) receptors. We further investigated the nature of the interaction between ibogaine and NMDA receptors in voltage clamp and binding studies, and sought to confirm that the drug has NMDA receptor blocking activity in vivo. In whole-cell recordings from cultured rat hippocampal neurons, ibogaine caused a slow, concentration-dependent block of NMDA-induced currents (IC50, 3.1 μM at -60 mV). In contrast, ibogaine failed to affect either kainate- or γ-aminobutyric acid-evoked currents. The blockade of NMDA currents was use- and voltage-dependent, and the long lasting ibogaine block could be occluded by coapplication of Mg2+. Ibogaine also inhibited equilibrium [3H]dizocilpine binding to NMDA receptors in rat forebrain membranes (IC50, 3.2 μM). We conclude that ibogaine is an open channel NMDA receptor antagonist. Administration of ibogaine to mice resulted in complete protection in the maximal electroshock test (ED50, 31 mg/kg, i.p.) and partial protection against NMDA-induced lethality, confirming that ibogaine can block NMDA receptors in vivo.",
keywords = "[H]dizocilpine binding, hippocampus, Ibogaine, maximal electroshock (MES) test, NMDA receptor, seizure, voltage clamp recording",
author = "Kang Chen and Kokate, {Tushar G.} and Donevan, {Sean D.} and Carroll, {F. Ivy} and Rogawski, {Michael A}",
year = "1996",
month = "4",
doi = "10.1016/0028-3908(96)84107-4",
language = "English (US)",
volume = "35",
pages = "423--431",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Ibogaine block of the NMDA receptor

T2 - In vitro and in vivo studies

AU - Chen, Kang

AU - Kokate, Tushar G.

AU - Donevan, Sean D.

AU - Carroll, F. Ivy

AU - Rogawski, Michael A

PY - 1996/4

Y1 - 1996/4

N2 - Ibogaine is an hallucinogenic indole alkaloid claimed to have anti- addictive properties. Although its mechanism of action is unknown, binding studies have indicated that the drug may interact with N-methyl-D-aspartate (NMDA) receptors. We further investigated the nature of the interaction between ibogaine and NMDA receptors in voltage clamp and binding studies, and sought to confirm that the drug has NMDA receptor blocking activity in vivo. In whole-cell recordings from cultured rat hippocampal neurons, ibogaine caused a slow, concentration-dependent block of NMDA-induced currents (IC50, 3.1 μM at -60 mV). In contrast, ibogaine failed to affect either kainate- or γ-aminobutyric acid-evoked currents. The blockade of NMDA currents was use- and voltage-dependent, and the long lasting ibogaine block could be occluded by coapplication of Mg2+. Ibogaine also inhibited equilibrium [3H]dizocilpine binding to NMDA receptors in rat forebrain membranes (IC50, 3.2 μM). We conclude that ibogaine is an open channel NMDA receptor antagonist. Administration of ibogaine to mice resulted in complete protection in the maximal electroshock test (ED50, 31 mg/kg, i.p.) and partial protection against NMDA-induced lethality, confirming that ibogaine can block NMDA receptors in vivo.

AB - Ibogaine is an hallucinogenic indole alkaloid claimed to have anti- addictive properties. Although its mechanism of action is unknown, binding studies have indicated that the drug may interact with N-methyl-D-aspartate (NMDA) receptors. We further investigated the nature of the interaction between ibogaine and NMDA receptors in voltage clamp and binding studies, and sought to confirm that the drug has NMDA receptor blocking activity in vivo. In whole-cell recordings from cultured rat hippocampal neurons, ibogaine caused a slow, concentration-dependent block of NMDA-induced currents (IC50, 3.1 μM at -60 mV). In contrast, ibogaine failed to affect either kainate- or γ-aminobutyric acid-evoked currents. The blockade of NMDA currents was use- and voltage-dependent, and the long lasting ibogaine block could be occluded by coapplication of Mg2+. Ibogaine also inhibited equilibrium [3H]dizocilpine binding to NMDA receptors in rat forebrain membranes (IC50, 3.2 μM). We conclude that ibogaine is an open channel NMDA receptor antagonist. Administration of ibogaine to mice resulted in complete protection in the maximal electroshock test (ED50, 31 mg/kg, i.p.) and partial protection against NMDA-induced lethality, confirming that ibogaine can block NMDA receptors in vivo.

KW - [H]dizocilpine binding

KW - hippocampus

KW - Ibogaine

KW - maximal electroshock (MES) test

KW - NMDA receptor

KW - seizure

KW - voltage clamp recording

UR - http://www.scopus.com/inward/record.url?scp=0029951464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029951464&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(96)84107-4

DO - 10.1016/0028-3908(96)84107-4

M3 - Article

VL - 35

SP - 423

EP - 431

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 4

ER -